- Conditions
- Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer
- Interventions
- Samuraciclib, Fulvestrant
- Drug
- Lead sponsor
- Carrick Therapeutics Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 5
- States / cities
- Ocala, Florida • Baltimore, Maryland • Kansas City, Missouri + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 477
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid System Neoplasm, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm
- Interventions
- Dexamethasone, Exercise Intervention, Placebo Administration
- Drug · Behavioral · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Heavy Menstrual Bleeding, Uterine Fibroid
- Interventions
- Relugolix, Estradiol/norethindrone acetate, Estradiol/norethindrone acetate placebo, Relugolix placebo
- Drug
- Lead sponsor
- Myovant Sciences GmbH
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 388 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 76
- States / cities
- Andalusia, Alabama • Mobile, Alabama • Little Rock, Arkansas + 62 more
- Conditions
- Heart Failure
- Interventions
- CLP, Spironolactone
- Drug
- Lead sponsor
- Sorbent Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Tustin, California
- Conditions
- Plasma Cell Myeloma, Residual Disease
- Interventions
- Ixazomib Citrate, Lenalidomide, Dexamethasone
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2024
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Acute Lymphoblastic Leukemia, Acute Undifferentiated Leukemia, Childhood T Acute Lymphoblastic Leukemia
- Interventions
- Asparaginase, Biospecimen Collection, Bone Marrow Biopsy, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Echocardiography, Etoposide, Filgrastim, Laboratory Biomarker Analysis, Lestaurtinib, Leucovorin Calcium, Mercaptopurine, Methotrexate, Methylprednisolone, Multigated Acquisition Scan, Pegaspargase, Pharmacological Study, Prednisone, Therapeutic Hydrocortisone, Vincristine Sulfate
- Drug · Procedure · Biological + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 1 Year
- Enrollment
- 218 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2024
- U.S. locations
- 157
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 120 more
- Conditions
- Recurrent Medulloblastoma, Recurrent Ependymoma
- Interventions
- Irinotecan, Temozolomide, Bevacizumab, Omburtamab I-131, Liothyronine, SSKI, Dexamethasone, Antipyretic, Antihistamine, anti-emetics
- Drug
- Lead sponsor
- Pediatric Brain Tumor Consortium
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 3
- States / cities
- Los Angeles, California • New York, New York • Cincinnati, Ohio
- Conditions
- Lung Cancer
- Interventions
- erlotinib hydrochloride, fulvestrant
- Drug
- Lead sponsor
- Translational Oncology Research International
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2018
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Diabetes (DM)
- Interventions
- Exendin-9 is a 30 amino acid peptide that is an established competitive antagonist of the GLP-1 receptor. Subjects will receive exendin-9 by intravenous infusion at a rate of 600 pmol/kg/min, Dexamethasone
- Drug
- Lead sponsor
- David D'Alessio, M.D.
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Vitiligo
- Interventions
- Needling, Triamcinolone
- Procedure · Drug
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Somerset, New Jersey
- Conditions
- Essential Hypertension
- Interventions
- LCI699, Eplerenone, LCI699-matching Placebo, Eplerenone-matching Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 628 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Preterm Delivery, Cervical Length
- Interventions
- 17 alpha-hydroxyprogesterone caproate, Placebo Oil
- Drug · Other
- Lead sponsor
- The George Washington University Biostatistics Center
- Other
- Eligibility
- Female only
- Enrollment
- 657 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2011
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Chicago, Illinois • Detroit, Michigan + 11 more
- Conditions
- Airway Management, Endotracheal Intubation
- Interventions
- Low-Dose Remifentanil, High-Dose Remifentanil, Succinylcholine, Rocuronium, Sugammadex
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 316 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Giant Cell Arteritis
- Interventions
- Tocilizumab, Prednisone, Tocilizumab Placebo, Prednisone Placebo, Corticosteroids, Methotrexate
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 251 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 14
- States / cities
- Los Angeles, California • Boca Raton, Florida • Sarasota, Florida + 10 more
- Conditions
- Aggressive Non-Hodgkin Lymphoma, ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Primary Mediastinal Large B-Cell Lymphoma, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Gray-Zone Lymphoma
- Interventions
- Polatuzumab Vedotin, Rituximab, Prednisone, Etoposide, Doxorubicin, Cyclophosphamide, Glofitamab, Multigated Acquisition Scan, Echocardiography Test, FDG-Positron Emission Tomography, Computed Tomography, Bone Marrow Biopsy, Biospecimen Collection, Bone Marrow Aspiration
- Drug · Biological · Procedure
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2031
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Graft Versus Host Disease
- Interventions
- Daclizumab, methylprednisolone, Placebo
- Biological · Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2004
- U.S. locations
- 8
- States / cities
- Boston, Massachusetts • Minneapolis, Minnesota • Buffalo, New York + 3 more
- Conditions
- Chronic Sinusitis
- Interventions
- PROPEL Mini Sinus Implant., Sinus Surgery alone, Propel Nova Sinus Implant
- Device · Procedure
- Lead sponsor
- Intersect ENT
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 10
- States / cities
- Sacramento, California • Torrance, California • Norwalk, Connecticut + 7 more
- Conditions
- Non-small Cell Lung Cancer, Postmenopausal Women
- Interventions
- fulvestrant (Faslodex), anastrozole (Arimidex), Bevacizumab (Avastin), Best supportive care
- Drug
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Puberty, Hyperandrogenism
- Interventions
- Micronized progesterone suspension, Placebo
- Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 10 Years to 17 Years · Female only
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2025
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Polycystic Ovary Syndrome, Infertility
- Interventions
- Progestin, Clomiphene Citrate
- Drug
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Shoulder Pain, Injury of Shoulder Region, Disorder of Shoulder, Disorder of Rotator Cuff, Disorder of Tendon of Biceps
- Interventions
- Dexamethasone, Bupivacaine
- Drug
- Lead sponsor
- Lifespan
- Other
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Newport, Rhode Island
- Conditions
- Castrate-Resistant Prostate Cancer
- Interventions
- ISIS EIF4E Rx, Prednisone, Docetaxel
- Drug
- Lead sponsor
- Ionis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 11
- States / cities
- Fayetteville, Arkansas • San Bernardino, California • Fort Collins, Colorado + 8 more
- Conditions
- Lymphoma
- Interventions
- rituximab, bortezomib, carboplatin, dexamethasone, etoposide, ifosfamide, polymerase chain reaction, western blotting
- Biological · Drug · Genetic
- Lead sponsor
- AIDS Malignancy Consortium
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 17
- States / cities
- La Jolla, California • Los Angeles, California • Sacramento, California + 12 more
- Conditions
- Frailty, Weakness, Muscle, Multiple Chronic Conditions
- Interventions
- Beta-hydroxymethyl butyrate supplement, Vitamin D supplement, Matching Beta-hydroxymethyl butyrate supplement without Vitamin D
- Dietary Supplement
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 65 Years to 85 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina